A study to compare Major Adverse Cardiac Event in patient undergoing PCI with Drug Eluting Stents Vs Bare Metal Stents

Chetan R. Patel*a, Mandev B. Patelb
a Singhania University, Jhunjhunu, Rajasthan, India
b K.B. Raval College of Pharmacy, Gandhinagar, Gujarat, India

ABSTRACT
This study compared Major Adverse Cardiac Event in patient with Acute Coronary Syndromes undergoing PCI with Drug Eluting Stents Vs Bare Metal Stents. A retrospective, observational study was carried out in an inpatient setting of the private tertiary care hospital. Patients with >18 years, diagnosed for Acute Coronary Syndromes (ACS), required intervention in coronary artery with implantation of Drug Eluting Stents (DES) or Bare Metal Stents (BMS) were recruited in the study. The data had been collected from file or database of the hospital. All subjects were followed for major adverse cardiac event. Result. A total of 202 patients who underwent percutaneous coronary intervention (PCI) were enrolled into DES group (N=101) and BMS group (N=101). All patients were followed up at 1 month, 3 months, 6 months & 12 months for Major Adverse Cardiac Events (MACE). Clinical outcomes during 12 months were compared between DES group & BMS group. There was no significant difference in baseline parameters including demographic, risk factors of ACS, diagnosis, angiographic parameters between both groups. Overall MACE rates were reported non-significantly high in BMS group patients (14.85%) compare to DES group patients (8.91%) (P=0.458). However, DES group had lower rates of death (0.99% vs 1.98%, P=0.57), rate of MI (3.96% vs 4.95% P=0.73), rate of revascularization (1.98% vs 3.96% p=0.42) & rate of sub acute thrombosis (1.98% vs 3.96% P=0.42) and higher rate of bleeding (1.98% vs 0.99% p=0.57) compare to cohort-II. Conclusion. The use of DES in the setting of Acute Coronary Syndrome is associated with lower Major Adverse Cardiac Event (MACE) rate compared to BMS without compromising the overall safety over the course of one-year follow-up. The long-term safety of drug-eluting stents needs to be ascertained in large, randomized trials.

Corresponding Author:
Chetan R. Patel
Singhania University, Jhunjhunu, Rajasthan, India
Email id: chetanniper@gmail.com
Contact no. +91 9898828311

1. INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death and disability in the world. Among these, coronary artery disease (CAD) is the most prevalent manifestation and is associated with high mortality and morbidity. India has the highest burden of acute coronary syndromes in the world, yet little is known about the treatments and outcomes of these diseases. There will be required to document the characteristics, treatments, and outcomes of patients with acute coronary syndromes who were admitted to hospitals in India.

Prospective, randomized clinical trials have shown that in-stent restenosis is reduced by the use of drug-eluting stents, as compared with bare-metal stents. However, the use of drug-eluting stents has rapidly
been expanded to all types of patients, including those with more complicated coronary lesions and in acute settings. Recently metaanalyses of randomized trials \[3-4\] and registries \[5\] have raised concern about incomplete neointimal coverage with a subsequent increase in late stent thromboses in patients with drug-eluting stents. \[6-7\] One randomized trial indicated that the implantation of drug-eluting stents was associated with an early reduction in death and myocardial infarction — an improvement that was lost during the subsequent 6 to 18 months by a late increase in the same events. \[8\] We determined that the evaluation of large clinical registries might provide useful information concerning the long-term efficacy and safety of drug-eluting stents. Therefore, we evaluated the long-term outcome in all patients who underwent stent implantation.

2. RESEARCH METHOD
A retrospective, open label, observational study carried out in an inpatient setting of the private tertiary care hospital. Patients with >18 years, diagnosed for Acute Coronary Syndromes (ACS), required intervention in coronary artery with implantation of Drug Eluting Stents (DES) or Bare Metal Stents (BMS) were recruited in the study. The data had been collected from file or database of the hospital. All subjects were followed for major adverse cardiac event (MACE) including death, Myocardial infarction, Urgent revascularization, sub acute thrombosis & bleeding at 1 month, 3 months, 6 months & 12 months after PCI. All collected data was analyzed in its group for clinical outcomes. All variables were analyzed using percentage, mean & standard deviation. Statistical difference between both cohorts was calculated by applying independent t-test & odds ratio.

3. RESULTS & ANALYSIS
There were 202 patients who underwent PCI between December 2008 and July 2009 was enrolled in retrospective, observational study. All these subjects were divided in two Cohorts.
Cohort-1: Patients implanted Drug Eluting Stent (DES) (N=101)
Cohort-2: Patients implanted Bare Metal stent (BMS) (N=101)

Table 1. Demographic parameters

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Cohort-I</th>
<th>Cohort-II</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>56.34 ± 10.93</td>
<td>55.46 ± 12.47</td>
<td>0.59</td>
</tr>
<tr>
<td>Gender-Male</td>
<td>87.13% (88)</td>
<td>89.11% (90)</td>
<td>0.66</td>
</tr>
<tr>
<td>Weight</td>
<td>68.02 ± 11.33</td>
<td>69.8 ± 0.29</td>
<td>0.29</td>
</tr>
<tr>
<td>Height</td>
<td>164.2 ± 9.55</td>
<td>164 ± 7.08</td>
<td>0.88</td>
</tr>
<tr>
<td>BMI</td>
<td>25.25 ± 3.81</td>
<td>28.87 ± 3.74</td>
<td>0.24</td>
</tr>
<tr>
<td>BSA</td>
<td>1.74 ± 0.17</td>
<td>1.76 ±0.17</td>
<td>0.48</td>
</tr>
</tbody>
</table>

Figure 1. Age wise distribution of patients
Out of the 202 patients, 87.13% (N=88) and 89.11% (N=90) were male patients in Cohort-1 & Cohort-2 respectively. The average age of the patients were 56.34 & 55.46 in Cohort-1 & Cohort-2 respectively (Table 1). Risk of acute coronary syndrome was increase with increasing age (Figure 1). Average BMI in cohort 1 & cohort 2 were 25.25 Kg/m$^2$ & 28.87 Kg/m$^2$ respectively. There was no significant difference in baseline demographic parameters between both groups (Table 1).

There were no significant difference in hypertension (46.53% Vs 33.66% P=0.74), diabetes Mellitus-II (30.69% Vs 21.78% P=0.15), family history of CAD (22.77% Vs 24.75% P=0.06), prior history of CAD (15.84% Vs 11.88% P=0.42), smoker (14.85% Vs 22.77% P=0.15), tobacco chewer (15.84% Vs 8.91% P=0.15), hyperlipidemia (1.98% Vs 1.98% P=1.00) in cohort-I & cohort-II respectively (Table 2).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Cohort-I</th>
<th>Cohort-II</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTN</td>
<td>46.53% (47)</td>
<td>33.66% (34)</td>
<td>0.74</td>
</tr>
<tr>
<td>DM-2</td>
<td>30.69% (31)</td>
<td>21.78% (22)</td>
<td>0.15</td>
</tr>
<tr>
<td>Family History</td>
<td>22.77% (23)</td>
<td>24.75% (25)</td>
<td>0.06</td>
</tr>
<tr>
<td>Smoker</td>
<td>14.85% (15)</td>
<td>22.77% (23)</td>
<td>0.15</td>
</tr>
<tr>
<td>Prior H/O CAD</td>
<td>15.84% (16)</td>
<td>11.88% (12)</td>
<td>0.42</td>
</tr>
<tr>
<td>Tobacco chewer</td>
<td>15.84% (16)</td>
<td>8.91% (9)</td>
<td>0.15</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>1.98% (2)</td>
<td>1.98% (2)</td>
<td>1.00</td>
</tr>
</tbody>
</table>

There were high number of subjects were reported as STEMI in both groups. STEMI was reported 35.64% (36) Vs 34.66% (35), p=0.88 in Cohort-1 & Cohort-2 respectively. NSTEMI was reported 27.73% (28) Vs 31.68% (32), p=0.54 in Cohort-1 & Cohort-2 respectively. Unstable angina was reported 29.7% (30) Vs 30.69% (31), p=0.88 in Cohort-1 & Cohort-2 respectively. Stable angina was reported 6.93% (7) Vs 2.97% (3), p=0.21 in Cohort-1 & Cohort-2 respectively (Figure 2).

During coronary angiography (CAG), It was found that the main culprit vessel in coronary artery disease was LAD (66.34% & 54.45% in Cohort-1 & Cohort-2 respectively) followed by RCA (21.78% & 23.76% in Cohort-1 & Cohort-2 respectively). There were high numbers of subjects having coronary stenosis >90% in both cohorts (49.5% & 52.47% in Cohort-1 & Cohort-2 respectively). Detail coronary angiographic findings were shown in Table 3.

Overall MACE rates were reported non-significantly high in Cohort-I (8.91%) compare to Cohort-II (14.85%) (P = 0.458). However, Cohort-I had lower rates of death (0.99% vs 1.98%, P=0.57), rate of MI
(3.96% vs 4.95% P=0.73), rate of revascularization (1.98% vs 3.96% p=0.42) & rate of sub acute thrombosis (1.98% vs 3.96% P=0.42) and higher rate of bleeding (1.98% vs 0.99% p=0.57) compare to cohort II (Figure 3).

Table 3. Angiographic findings

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Cohort-I</th>
<th>Cohort-II</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of Vessel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAD</td>
<td>66.34% (67)</td>
<td>54.45% (55)</td>
<td>0.09</td>
</tr>
<tr>
<td>RCA</td>
<td>21.78% (22)</td>
<td>23.76% (24)</td>
<td>0.74</td>
</tr>
<tr>
<td>LAD &amp; RCA</td>
<td>4.95% (5)</td>
<td>3.96% (4)</td>
<td>0.73</td>
</tr>
<tr>
<td>LCX</td>
<td>3.96% (4)</td>
<td>10.89% (11)</td>
<td>0.07</td>
</tr>
<tr>
<td>RAMUS</td>
<td>1.98% (2)</td>
<td>0% (0)</td>
<td>0.29</td>
</tr>
<tr>
<td>SVG Graft</td>
<td>0.99% (1)</td>
<td>0% (0)</td>
<td>0.50</td>
</tr>
<tr>
<td>OM-2</td>
<td>0% (0)</td>
<td>3.96% (4)</td>
<td>0.14</td>
</tr>
<tr>
<td>LCX &amp; LAD</td>
<td>0% (0)</td>
<td>0.99% (1)</td>
<td>0.50</td>
</tr>
<tr>
<td>LMCA</td>
<td>0% (0)</td>
<td>0.99% (1)</td>
<td>0.50</td>
</tr>
<tr>
<td>RCA &amp; LCX</td>
<td>0% (0)</td>
<td>0.99% (1)</td>
<td>0.50</td>
</tr>
<tr>
<td>Lesion Class</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>13.86% (14)</td>
<td>14.85% (15)</td>
<td>0.84</td>
</tr>
<tr>
<td>B1</td>
<td>20.79% (21)</td>
<td>22.77% (23)</td>
<td>0.73</td>
</tr>
<tr>
<td>B2</td>
<td>25.74% (26)</td>
<td>25.74% (26)</td>
<td>1.00</td>
</tr>
<tr>
<td>C</td>
<td>39.6% (40)</td>
<td>36.63% (37)</td>
<td>0.66</td>
</tr>
<tr>
<td>% stenosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;90%</td>
<td>49.5% (50)</td>
<td>52.47% (53)</td>
<td>0.67</td>
</tr>
<tr>
<td>80-90%</td>
<td>48.51% (49)</td>
<td>44.55% (45)</td>
<td>0.57</td>
</tr>
<tr>
<td>&lt;80%</td>
<td>1.98% (2)</td>
<td>2.97% (3)</td>
<td>0.65</td>
</tr>
<tr>
<td>Calcification</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None/Mild</td>
<td>72.27% (73)</td>
<td>70.29% (71)</td>
<td>0.76</td>
</tr>
<tr>
<td>Moderate</td>
<td>19.8% (20)</td>
<td>19.8% (20)</td>
<td>1.00</td>
</tr>
<tr>
<td>Severe</td>
<td>7.92% (8)</td>
<td>9.9% (10)</td>
<td>0.62</td>
</tr>
<tr>
<td>Tortuosity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;45</td>
<td>90.09% (91)</td>
<td>82.17% (83)</td>
<td>0.11</td>
</tr>
<tr>
<td>45-90</td>
<td>9.9% (10)</td>
<td>17.82% (18)</td>
<td>0.11</td>
</tr>
<tr>
<td>Thrombus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>41.58% (42)</td>
<td>52.47% (53)</td>
<td>0.12</td>
</tr>
<tr>
<td>1</td>
<td>34.65% (35)</td>
<td>23.76% (24)</td>
<td>0.09</td>
</tr>
<tr>
<td>2</td>
<td>18.81% (19)</td>
<td>14.85% (15)</td>
<td>0.45</td>
</tr>
<tr>
<td>3</td>
<td>4.95% (5)</td>
<td>8.91% (9)</td>
<td>0.27</td>
</tr>
</tbody>
</table>

Over all MACE rate reported for both of the groups was 0.99% Vs 0.99% (P=1) at one month, 0.99% Vs 2.97% (P=0.34) at three months, 2.97% Vs 3.96% (P=0.7) at six months and 3.96% Vs 6.93% (P=0.36) at twelve months in Cohort-1 & Cohort-2 respectively (Figure 4).

Safety and efficacy study result demonstrated that over all MACE and mortality rate appears lower in DES group compare to BMS group. However, it was not significant statistically. Further long term study is required to get more viable results with larger population.
4. CONCLUSION

Our study compared the clinical outcome of drug-eluting stents versus bare-metal stents in a large cohort patients treated with coronary stents at Private tertiary care hospital. The long-term follow-up was complete. There was a trend toward a lower event rate during the initial 6 months and a consistently higher event rate thereafter. The likelihood that these events were caused by stent thrombosis is strengthened by the demonstration of incomplete neointimal coverage as a probable reason for late stent thromboses in patients with drug-eluting stents. Safety and efficacy study result demonstrated that overall MACE and mortality rate appears lower in DES group compare to BMS group. However, it was not significant statistically. Further long term study is required to get more viable results with larger population.
REFERENCES


